Strategies to accelerate RNA-based nanomedicine development

Cytiva’s BioPharma Services team offers outsourcing strategies to advance and accelerate nanomedicine development. When collaborating with Replicate Bioscience, our team was able to combine an innovative payload technology (self-replicating RNA vector) with our delivery expertise for LNP formulation, including a Cytiva proprietary ionizable lipid, to develop a novel rabies vaccine with recent favorable readout in a phase 1 clinical trial.

Replicate Bioscience and Cytiva’s collaboration exemplifies the combined power for advancing innovative RNA therapeutics. Through access to proprietary ionizable lipids, advanced LNP technology, and comprehensive analytical and regulatory support, Replicate Bioscience was able to accelerate the development of its srRNA platform and clinical evaluation. It demonstrates how a strong collaboration can drive scientific innovations from the lab to the clinic.